Heartland Bank & Trust’s Biogen BIIB Stock Holding History

Heartland Bank & Trust’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-2,265	Closed	-$555K	–	115
2020 Q4	$555K	Buy	+2,265	New	+$584K	0.49%	62

Other funds holding BIIB

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Heartland Bank & Trust's BIIB Position: Q1 2021 in Review

Heartland Bank & Trust sold out of Biogen (BIIB) in Q1 2021, closing a stake of 2,265 shares — an estimated $555K sold.

Heartland Bank & Trust first reported a position in BIIB in Q4 2020 and held it in 1 quarter. The position peaked at $555K in Q4 2020. 1,093 funds tracked by Wall St. Rank hold BIIB as of Q1 2021.

Heartland Bank & Trust reported no remaining Biogen position as of Q1 2021 after selling out during the quarter.
Heartland Bank & Trust sold 2,265 Biogen shares in Q1 2021, an estimated $555K.
Heartland Bank & Trust first reported a position in Biogen in Q4 2020 and held it in 1 quarter.
Heartland Bank & Trust's Biogen position peaked at $555K in Q4 2020.
1,093 funds tracked by Wall St. Rank held Biogen as of Q1 2021.

Based on Heartland Bank & Trust's 13F filing for Q1 2021, filed 21 Jun 2021.